Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury [Corrigendum]
Mizuno T, Sato W, Ishikawa K, et al. Onco Targets Ther. 2015;8:1701–1706.
On page 1703, Figure 1, the y-axis label for parts A and B should have read “Fold change (MATE/SLC47A1 mRNA/GAPDH mRNA)” rather than “Fold change (TG2 mRNA/GAPDH mRNA)”. “TG2, transglutaminase 2” also should be removed from the abbreviations list.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]